Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ACT-PC

Financiado

Actionable metabolite supplements to improve treatment response in pancreatic ca...

Actionable metabolite supplements to improve treatment response in pancreatic cancer The prognosis with metastatic pancreatic ductal adenocarcinoma PDAC is simply terrible, especially for those that do not respond to the chemotherapy, which is regarded as the standard therapy in most patients. More than half of th... ver más

31/10/2025

UKE

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-14

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

UKE

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-125981OB-I00 TRATAMIENTO DE CANCER DE PANCREAS CON RADIACION LOCAL IONIZA... 212K€ Cerrado

PLEC2022-009337 NUEVAS ESTRATEGIAS DE INMUNOTERAPIA PARA EL TRATAMIENTO DE C... 916K€ Cerrado

PLEC2021-008094 Targeting the tumor microenvironment to improve CAR-T cell b... 104K€ Cerrado

BasicFit Targeting bicarbonate transport as a first-in-class therapeu... 150K€ Cerrado

RTI2018-096455-B-I00 INHIBIDORES DE TIROSINA QUINASAS DUALES EN CANCER DE PANCREA... 157K€ Cerrado

PID2021-123056OA-I00 UROLITINAS PRODUCIDAS POR LA MICROBIOTA: UN NUEVO PARADIGMA... 157K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2024-03-14
Fecha Fin: 2025-10-31

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The prognosis with metastatic pancreatic ductal adenocarcinoma PDAC is simply terrible, especially for those that do not respond to the chemotherapy, which is regarded as the standard therapy in most patients. More than half of the patients are non-responders and eventually pass away within months. It is therefore urgently needed to understand the differences among responder and non-responder patients, to develop alternative therapies that overcome the resistance and potentially further extend the survival for both groups. A recent hypothesis proposes the key role of microbiome and of the immune response in regard to tumor initiation, progression, as well as response to therapies. Diet, as a variable, introduces an additional layer of complexity, given its multifaceted impact on both the human microbiome and immune system, as our recent manuscript show. The metabolites produced by gut microbiota are influenced not only by diet, but also by a host of other factors. In ACT-PC, we propose the use of one or a combination of different microbiota-derived metabolites as a treatment to increase the efficacy of chemotherapy and at the same time to boost anti tumor immunity for PDAC patients. The overall goal of ACT-PC is to initiate the preclinical validation of specific microbiota-derived metabolites for improving treatment outcomes in PDAC patients. This project is designed to take our Technology Readiness Level from 2 to 4, enabling us to finalise the preclinical development within a subsequent EIC Transition and initiate clinical validation and development soon after. In implementing the project’s results we will leverage the PI’s unique network that includes commercial partners and patient organisations.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores